Julphar Diabetes Symposium Held with Global Experts in Dubai
DUBAI, UAE, September 6, 2012 /PRNewswire/ –
Julphar Diabetes hosted its inaugural Diabetes Symposium in Dubai today. Attended by
over 100 influential healthcare decision-makers from across the MENA region, the symposium
discussed some of the key challenges posed by the rise of the global diabetes epidemic.
During the event delegates, who had travelled from the UAE, KSA, Iraq, Algeria.
Tunisia, Libya, Lebanon, Yemen, Kenya, Ethiopia and Egypt, listened to presentations from
two of the world’s most eminent experts in the field of diabetes care, Dr. Jay S. Skyler
and Dr. Mary Angelyn Bethel.
Speaking at the Symposium during which he addressed attendees on ‘Future Approaches to
Diabetes’, Dr Skyler said: ”Diabetes is a growing global problem and the Middle East has
its own specific challenges in dealing with this disease which need to be addressed by
healthcare providers on a local level. I applaud this initiative, which enables open
discussion and shared learning amongst the professionals shaping the sector.
Dr Skyler is a Professor of Medicine, Pediatrics and Psychology at the University of
Miami Miller School of Medicine and Deputy Director for Clinical Research and Academic
Programs at the Diabetes Research Institute (DRI). His career in diabetes spans over four
decades, where his research interests have concentrated in clinical aspects of diabetes,
particularly improving the care of Type 1 diabetes through meticulous glycemic control,
psychosocial and behavioural support, and immune intervention.
Dr Bethel added, ‘events such as these help to focus our thoughts and address the very
real issues and challenges we face as practitioners in the field of diabetes care. Julphar
Diabetes is a leading light in the fight against diabetes not only in the GCC and Middle
East but also on an international level and we must all applaud their continuous
commitment and investment.’
Dr Bethel is currently the Deputy Director, Diabetes Trials Unit, at the Oxford Centre
for Diabetes, Endocrinology, and Metabolism at the Churchill Hospital, in the UK.
At the Symposium she tackled the Role of Glucose Control in Managing Cardiovascular
Risk in which she reviewed the strength of the association between hyperglycaemia and
cardiovascular outcomes and the evidence that improving glycaemia control lowers
Joe Saldanha, GM of Julphar Diabetes, hailed the event as a great success. Closing the
Symposium he said: ‘This Symposium has been a tremendous platform to highlight what is
surely one of the biggest health issues of the 21st century. We have been privileged to
have with us some of the world’s leading endocrinologists on this subject and we have
clearly gained significant knowledge from their insights. I look forward to continuing to
work with them in combating the rise of diabetes on a global scale and hope that when we
next meet altogether we will be able to witness some demonstrable improvement in some of
the key issues we have been discussing here today.’
Julphar Diabetes is the division of Julphar that manages the manufacturing and
commercialization of diabetes products. Following the Symposium, guests visited the newly
opened $150m Julphar Diabetes facility (Julphar XI). The plant is built in accordance with
the latest EMEA regulations, utilizing the best available technologies in the market to
comply with the latest international quality standards, thus making it one of the most
modern bio-technological plants designed for producing insulin crystals. Production
capacity is expected to be around 40 million vials of insulin per year, enough to supply
the entire region and beyond.
Notes to Editors:
Julphar is a public shareholding company based in Ras Al Khaimah (UAE). It was
established in 1980 under the guidance of H H Sheikh Saqr Bin Mohammed Al Qasimi, the
Ruler of Ras Al Khaimah, and is currently a leader in the production and distribution of
Since inception, Julphar remains committed to meeting the needs of an evolving society
and playing an instrumental role in global healthcare development. Its approach to a fast
paced market is to focus on strategic initiatives, quality product development and
ensuring responsible practices.
Julphar’s goal is to create innovative and high-quality products, whilst maintaining a
competitive cost. This is achieved through ten world-class plants based in the UAE, and a
reliable transportation network which covers five continents.
Julphar contains a diverse portfolio of products which targets a large range of major
therapeutic segments, including cardiovascular, diabetes, gynecology and other consumer
Photo: http://photos.prnewswire.com/prnh/20120906/559494-a http://photos.prnewswire.com/prnh/20120906/559494-b http://photos.prnewswire.com/prnh/20120906/559494-c http://photos.prnewswire.com/prnh/20120906/559494-d